ALTO vs LIN
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
ALTO's deterministic health scores reveal significant concerns: a Piotroski F-Score of 2/9 indicates weak financial health, and the absence of an Altman Z-Score raises distress risk concerns. Despite this, the stock trades at a discount to its Graham Number ($3.38) and intrinsic value ($1.12), suggesting potential undervaluation. The recent earnings surprise history is volatile but highly positive in the most recent quarters, with a 75% Q/Q EPS growth and 149% YoY EPS growth. Strong price momentum—253% 1-year return and 294.9% 6-month return—reflects market optimism, supported by a strong-buy analyst consensus. However, the company's negative revenue growth (-1.90% YoY) and minimal profitability (1.45% profit margin) remain critical red flags. Price trades at a 37.9% premium to fair value estimate ($3.38), limiting near-term upside from a valuation perspective.
LIN shows neutral fundamentals based on deterministic rules. Financial strength is stable (F-Score 4/9). Mixed signals with both opportunities and risks present.
Compare Another Pair
Related Comparisons
ALTO vs LIN: Head-to-Head Comparison
This page compares Alto Ingredients, Inc. (ALTO) and Linde plc (LIN) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.